- Home
- SBLK vs TARS Comparison
SBLK vs TARS Comparison
Compare SBLK & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBLK | TARS |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SBLK | TARS |
|---|---|---|
| Price | $27.10 | $60.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $25.50 | ★ $89.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $11.56 | $56.43 |
| Revenue Next Year | N/A | $30.19 |
| P/E Ratio | $47.06 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $16.72 | $38.51 |
| 52 Week High | $28.50 | $85.25 |
Technical Indicators
Market Signals| Indicator | SBLK | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 49.15 |
| Support Level | $26.06 | $56.05 |
| Resistance Level | $27.29 | $67.14 |
| Average True Range (ATR) | 0.76 | 3.38 |
| MACD | 0.19 | -0.11 |
| Stochastic Oscillator | 62.71 | 37.27 |
Price Performance
Historical ComparisonAbout SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. The firm generates the majority of its revenue from Time charters and Voyage charters.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.